Serum HDAC3 as an Early Indicator for Predicting and Staging Acute Kidney Injury Associated with Sepsis: A Prospective Cohort Analysis - Scorecard - MDSpire
Advertisement
Serum HDAC3 as an Early Indicator for Predicting and Staging Acute Kidney Injury Associated with Sepsis: A Prospective Cohort Analysis
Clinical Scorecard: Serum HDAC3 as an Early Indicator for Predicting and Staging Acute Kidney Injury Associated with Sepsis: A Prospective Cohort Analysis
At a Glance
Category
Detail
Condition
Sepsis-associated acute kidney injury (SA-AKI)
Key Mechanisms
Dysregulated host response to infection, inflammation, mitochondrial dysfunction, and reactive oxygen species production.
Target Population
Patients diagnosed with sepsis requiring ICU admission.
Care Setting
Intensive Care Unit (ICU)
Key Highlights
Over 40% of sepsis patients develop AKI, with a mortality rate of 50% to 70%.
Traditional markers like serum creatinine are insufficient for early AKI diagnosis.
HDAC3 may serve as a sensitive biomarker for early identification of SA-AKI.
The study aims to evaluate serum HDAC3 levels as a predictive tool for AKI onset within 7 days.
Guideline-Based Recommendations
Diagnosis
Use KDIGO criteria for diagnosing and staging AKI.
Management
Monitor serum HDAC3 levels for early identification of SA-AKI.
Monitoring & Follow-up
Daily measurement of serum creatinine and HDAC3 levels post-ICU admission.
Risks
Patients with severe comorbid conditions may be excluded from the study.
Patient & Prescribing Data
Patients diagnosed with sepsis according to Sepsis-3 criteria.
Selective HDAC3 inhibition may reduce renal injury in experimental models.
Clinical Best Practices
Implement early monitoring of serum HDAC3 levels in sepsis patients.
Consider AKI risk factors and comorbidities when assessing patients.
